Transient asymptomatic pulmonary opacities and interstitial lung disease in EGFR -mutated non-small cell lung cancer treated with osimertinib.

TAPO are benign pulmonary findings observed in patients treated with osimertinib. TAPO variability in terms of CT features can hinder the differential diagnosis with either osimertinib-related mild ILD or tumor progression. However, because TAPO are asymptomatic, it could be reasonable to continue therapy and verify the resolution of the CT findings at follow-up in selected cases.